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are rare reports of serious hypersensitivity reactions related to topical chlorhexidine use or following exposure to chlor hexidine-impregnated devices. 5, 6 Skin inflammation was re ported in 15% and 27% of patients, respectively, who par ticipated in 2 studies of chlorhexidine; however, neither study identified any local or systemic hypersensitivity reactions. 7, 8 Outside of research studies, it is unclear how the use of chlor hexidine is limited by reactions to this agent and how per ceived intolerance to chlorhexidine varies between facilities. In order to better understand the prevalence of perceived chlorhexidine intolerance, we queried groups participating in the CDC Dialysis BSI Prevention Collaborative about their experience with this antiseptic.
We provided questionnaires to 5 groups in the collabo ration who agreed to participate in this evaluation. The in strument consisted of 24 questions from the following do mains: facility demographics, facility chlorhexidine use practices, and prevalence of chlorhexidine-intolerant patients. Intolerance to chlorhexidine was simply defined as a patient who was eligible to receive chlorhexidine for skin antisepsis but who was unable to use this antiseptic because of a per ceived adverse reaction. The questionnaire was primarily de signed to determine how many of a facility's active patients were unable to receive chlorhexidine for skin antisepsis on the basis of the facility's own criteria. We did not evaluate those criteria or impose uniform criteria on respondents. Analyses were stratified by vascular access type (ie, central line, AV graft, or AV fistula).
Five individuals were queried and responded from March 25, 2011 to April 26, 2011. They reported information from 18 facilities that cared for 586 patients. Overall, all 18 facilities used chlorhexidine for skin antisepsis for patients who had central lines (290 patients), 10 used chlorhexidine for patients who had AV fistulae (256 patients), and 10 used chlorhexidine for patients who had AV grafts; however, 2 facilities had no patients with AV grafts who were currently receiving chlor hexidine, and this reduced the evaluable number of facilities in that category to 8 (40 patients). For patients who had central lines, 1 facility used 2% aqueous chlorhexidine, 14 used 2% chlorhexidine with 70% alcohol, and 3 used 4% chlorhexidine with 4% alcohol. For patients who had AV fistulae, 7 facilities used 2% chlorhexidine with 70% alcohol and 3 used 3.15% chlorhexidine with 70% alcohol. For pa tients who had AV grafts, 6 facilities used 2% chlorhexidine with 70% alcohol and 2 used 3.15% chlorhexidine with 70% alcohol.
Overall, 97 of 586 patients (17%) were unable to use chlor hexidine because of perceived intolerance. This included 35 (12%) of 290 patients with central lines, 53 (21%) of 256 patients with AV fistulae, and 9 (23%) of 40 patients with AV grafts (P for difference between 3 groups = .02). When stratified by access type, there was a high level of variability in the proportion of patients per facility who were unable to use chlorhexidine because of a perceived intolerance (Table  1 ). In addition, more than 25% of patients were intolerant to chlorhexidine in a sizable proportion of facilities (Table  1) .
These data suggest that in the Centers for Disease Control and Prevention (CDC) Dialysis BSI Prevention Collaborative, perceived chlorhexidine intolerance is not uncommon and is found more commonly among patients with AV grafts and AV fistulae than among patients with central lines. In addi tion, the proportion of patients in each facility who had per ceived chlorhexidine intolerance varied from 0 to about onehalf of eligible patients. This level of heterogeneity suggests that variations in practices among facilities might explain some of the intolerance and implies that more standardized practices might improve chlorhexidine use. However, as we did not assess each facility's threshold for discontinuing chlor hexidine use, differences in those criteria might also explain some of the variability in chlorhexidine intolerance we ob served.
As chlorhexidine is an important agent for skin antisepsis, further work is needed to clarify practices that will increase the number of patients who are able use this agent. This includes better defining what constitutes a significant adverse reaction. In this evaluation, we were unable to assess differ ences in adverse reactions between chlorhexidine products and we do not know whether the level of chlorhexidine in tolerance was different than that observed for other skin an tiseptics. Preliminary work in facilities in the CDC collabo rative that followed this evaluation suggests that ensuring that the chlorhexidine had time to dry prior to covering it with an occlusive dressing and less vigorous scrubbing of the skin during chlorhexidine application were associated with a de crease in adverse reactions. A better understanding of the issues surrounding perceived intolerance has the potential to lead to increased use of chlorhexidine and decreases in BSIs among patients receiving hemodialysis. 
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